[go: up one dir, main page]

UA90597C2 - Противораковое лечение комбинацией таксанов и 13-дезоксиантрациклинов - Google Patents

Противораковое лечение комбинацией таксанов и 13-дезоксиантрациклинов

Info

Publication number
UA90597C2
UA90597C2 UAA200813376A UAA200813376A UA90597C2 UA 90597 C2 UA90597 C2 UA 90597C2 UA A200813376 A UAA200813376 A UA A200813376A UA A200813376 A UAA200813376 A UA A200813376A UA 90597 C2 UA90597 C2 UA 90597C2
Authority
UA
Ukraine
Prior art keywords
deoxyanthracyclines
taxanes
combination
anticancer treatment
taxane
Prior art date
Application number
UAA200813376A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ричард Д. Олсон
Джеральд М. Волш
Original Assignee
ДЖЕМ ФАРМАСЬЮТИКАЛС, ЛЛСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ДЖЕМ ФАРМАСЬЮТИКАЛС, ЛЛСи filed Critical ДЖЕМ ФАРМАСЬЮТИКАЛС, ЛЛСи
Publication of UA90597C2 publication Critical patent/UA90597C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение касается противоракового лечения путем введения в организм 13-дезоксиантрациклина и таксана (палитакселя или доцетакселя) одновременно, отдельно или последовательно для получения противоракового эффекта с уменьшенным профилем токсичности и побочных эффектов по сравнению с введением равноэффективных количеств любого соединения отдельно.
UAA200813376A 2006-04-21 2007-04-23 Противораковое лечение комбинацией таксанов и 13-дезоксиантрациклинов UA90597C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/408,000 US7776832B2 (en) 2006-04-21 2006-04-21 Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines

Publications (1)

Publication Number Publication Date
UA90597C2 true UA90597C2 (ru) 2010-05-11

Family

ID=38620193

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200813376A UA90597C2 (ru) 2006-04-21 2007-04-23 Противораковое лечение комбинацией таксанов и 13-дезоксиантрациклинов

Country Status (20)

Country Link
US (2) US7776832B2 (ru)
EP (1) EP2010191B1 (ru)
JP (1) JP5011377B2 (ru)
KR (1) KR101514336B1 (ru)
CN (1) CN101426509A (ru)
AU (1) AU2007240264B2 (ru)
CA (1) CA2649753C (ru)
CO (1) CO6190526A2 (ru)
DK (1) DK2010191T3 (ru)
ES (1) ES2840977T3 (ru)
IL (1) IL194707A (ru)
MX (1) MX2008013546A (ru)
MY (1) MY148571A (ru)
NZ (1) NZ572012A (ru)
PL (1) PL2010191T3 (ru)
PT (1) PT2010191T (ru)
RU (1) RU2421224C2 (ru)
UA (1) UA90597C2 (ru)
WO (1) WO2007124489A2 (ru)
ZA (1) ZA200808892B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101476626B1 (ko) * 2009-01-30 2014-12-26 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염을 예방하거나 치료하기 위한 사이클로스포린 유사체
US8481483B2 (en) * 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) * 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) * 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) * 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8623814B2 (en) * 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
DK2707030T3 (da) 2011-05-09 2020-05-18 Mayo Found Medical Education & Res Cancerbehandlinger
AU2013327638B2 (en) 2012-10-01 2018-06-14 Mayo Foundation For Medical Education And Research Cancer treatments
CN106573051B (zh) 2014-06-13 2021-07-13 梅约医药教育及研究基金会 治疗淋巴瘤
CN106604750B (zh) 2014-06-16 2021-05-07 梅约医学教育与研究基金会 治疗骨髓瘤
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
EP3265059A4 (en) * 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
US11351254B2 (en) 2016-02-12 2022-06-07 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432928A4 (en) * 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
WO2017165440A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
EP4177271A1 (en) 2016-09-01 2023-05-10 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
US11160876B2 (en) 2016-09-01 2021-11-02 Mayo Foundation For Medical Education And Research Methods and compositions for targeting t-cell cancers
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
JP7025412B2 (ja) 2016-09-06 2022-02-24 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ パクリタキセル－アルブミン－結合剤組成物並びに該組成物の使用及び製造方法
KR102486057B1 (ko) 2016-09-06 2023-01-10 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Ｐｄ－ｌ１ 발현 암의 치료 방법
US10450340B2 (en) * 2017-02-16 2019-10-22 Monopar Therapeutics Inc. 3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
EP4218820A3 (en) * 2017-03-16 2023-09-20 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1098211B (it) * 1978-05-09 1985-09-07 Farmaceutici Italia Deossiantracicline antitumorali
US5948896A (en) * 1997-08-13 1999-09-07 Gem Pharmaceuticals Processes for preparing 13-deoxy anthracycline derivatives
US5942605A (en) * 1998-03-03 1999-08-24 Gem Pharmaceuticals, Inc. 5-imino-13-deoxy anthracycline derivatives, their uses, and processes for preparing them
CZ20012508A3 (cs) 1999-01-13 2002-02-13 Genentech, Inc. Inhibitory serinové proteázy
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
GB0003201D0 (en) * 2000-02-11 2000-04-05 Pharmacia & Upjohn Spa Method to potentiate the therapeutic efficacy of taxane and derivatives thereof
MEP16308A (en) * 2002-05-17 2010-06-10 Aventis Pharma Sa Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
US9904704B2 (en) 2014-04-22 2018-02-27 Openx Software Limited System and method for controlling audience data and tracking

Also Published As

Publication number Publication date
MY148571A (en) 2013-04-30
MX2008013546A (es) 2009-01-20
NZ572012A (en) 2011-09-30
CO6190526A2 (es) 2010-08-19
US8158591B2 (en) 2012-04-17
PT2010191T (pt) 2021-01-04
ES2840977T3 (es) 2021-07-07
JP2009534426A (ja) 2009-09-24
BRPI0711256A2 (pt) 2011-08-30
US20070249547A1 (en) 2007-10-25
KR101514336B1 (ko) 2015-04-22
WO2007124489A2 (en) 2007-11-01
US20100311679A1 (en) 2010-12-09
RU2421224C2 (ru) 2011-06-20
IL194707A (en) 2015-10-29
JP5011377B2 (ja) 2012-08-29
ZA200808892B (en) 2009-10-28
PL2010191T3 (pl) 2021-05-04
CA2649753C (en) 2011-09-27
WO2007124489A3 (en) 2008-10-23
RU2008141682A (ru) 2010-05-27
KR20090010981A (ko) 2009-01-30
AU2007240264A1 (en) 2007-11-01
CN101426509A (zh) 2009-05-06
EP2010191A4 (en) 2010-05-26
EP2010191B1 (en) 2020-10-07
IL194707A0 (en) 2009-08-03
US7776832B2 (en) 2010-08-17
EP2010191A2 (en) 2009-01-07
DK2010191T3 (da) 2020-12-14
CA2649753A1 (en) 2007-11-01
AU2007240264B2 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
UA90597C2 (ru) Противораковое лечение комбинацией таксанов и 13-дезоксиантрациклинов
NZ621433A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
WO2008101214A3 (en) Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
MX2012001654A (es) Metodos para usar moduladores de c-met.
WO2009124266A3 (en) Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
DOP2006000057A (es) Composición farmaceútica para el tratamiento del cáncer
NZ588913A (en) Liver cancer drug
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
NZ595767A (en) Composition for the treatment of prostate cancer
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
MY154970A (en) Dimers of artemisinin derivatives, preparation thereof and therapeutic use thereof
MY150682A (en) Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
WO2012142615A3 (en) Auranofin and auranofin analogs useful to treat proliferative disease and disorders
WO2010121675A3 (en) Thiazolyl-benzimidazoles
NZ596226A (en) Antitumor combination including cabazitaxel and capecitabine
MX2007004955A (es) Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
MX355388B (es) Composiciones farmaceuticas y metodos terapeuticos que emplean una combinacion de un compuesto complejo de manganeso y una forma compleja no de manganeso del compuesto.
MX2010001084A (es) Tratamiento de tumores pediatricos.
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
MX2007001206A (es) Metodos para tratar la piel para mejorar el tratamiento terapeutico de la misma.
CL2008002465A1 (es) Composición farmacéutica anhidra tópica, que comprende derivados de niacina y un portador aceptable, su aplicacón permite un bienestar sexual mejorado.